ArticleCell communication and signaling : CCS2025
Epigenetic regulation of NR5A2 influences colorectal cancer cell stemness via a stemness-related transcription factor NANOG.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveColorectal cancer (CRC) is an aggressive malignancy with high mortality, and the identification of upstream regulators of stemness represents a critical step toward developing more effective targeted therapies. This study aimed to define the role of NR5A2 in CRC, particularly in the context of cancer stem cells (CSCs).
methodsWe profiled DNA copy number alterations, DNA methylation status, and mRNA expression in 30 CRC specimens. Primary CRC cells and CSC-enriched sphere cultures were established in vitro. Functional assays included RNA sequencing, sphere- and colony-formation assays, cell viability and cytotoxicity assessments, qRT-PCR, western blotting, immunofluorescence staining, chromatin immunoprecipitation (ChIP), and in vivo patient-derived xenograft (PDX) models.
resultsIntegrated genomic and epigenomic analyses implicated NR5A2 in the progression of an aggressive CRC subtype characterized by stemness gene expression. Our findings demonstrate that NR5A2 plays a key role in CRC. Mechanistically, NR5A2 promoted CSC maintenance by directly binding to the promoter and enhancer regions of NANOG, thereby upregulating its expression. Pharmacological inhibition of NR5A2 using Cmp3 significantly sensitized a subset of CRC PDX models to standard chemotherapy, resulting in enhanced tumor regression.
conclusionThis study identifies NR5A2 as a novel, actionable therapeutic target in CRC. Pharmacological modulation of NR5A2 disrupts CSC-driven stemness, potentially preventing relapse and improving treatment outcomes. These findings provide a strong rationale for the development of NR5A2-targeted therapies, either as monotherapy or in combination with chemotherapy, to optimize CRC patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.